Header

Skip to main content

Slider

Amyloidosis: The Road to Diagnosis

As a rare disease with a wide range of symptoms, Amyloidosis can be difficult for doctors to recognize. The disease presents itself differently depending on the type of Amyloidosis and which organs are affected. Delays in diagnosis are common, and some suffer for years while seeking answers. As a result, the road to diagnosis is often too long and winding, resulting in serious consequences for patients.

According to a survey of 575 patients conducted by Mackenzie’s Mission in 2019, over 60% of patients surveyed saw between two and four doctors before receiving a diagnosis, and another 24% saw five or more.

 

We reached out to our Amyloidosis community and asked them to share their road to diagnosis. Hear from Lisa, Len, Jan, Janet, and Laura, as they share their unique symptoms and struggles in receiving their Amyloidosis diagnosis.

 

Lisa

Lisa was diagnosed with Tracheobronchial Amyloidosis in 2011. She was 41 years old and had only 39% lung function. After working as a first responder for ASPCA in post-Katrina New Orleans, Lisa began having breathing problems. She assumed it was a reaction to the dust and debris she was exposed to in the hurricane zone.

In 2006 she was diagnosed as being severely asthmatic and was treated with inhalers and nebulizers. None of the treatments improved her symptoms and caused multiple side effects, including manic episodes and weight gain. Her health continued to decline.

Now unable to work due to her breathing problems, Lisa moved back home with her elderly mother in New York. She continued to seek treatment while rapidly losing lung function.

Finally, in 2011, she once again switched pulmonologists in her search for answers. Lisa’s new doctor took her off the steroids and did a bronchoscopy. They found a 2cm mass in her trachea, a mass so big it prevented the scope from going into her lungs. A biopsy, including congo red stain, revealed a diagnosis of Amyloidosis. Lisa’s was the first case of Tracheobronchial Amyloidosis diagnosed at the Albany Medical Centre in New York.

Thankfully, Lisa’s pulmonologist referred her to Dr.Berk at the Boston Medical Centre. After treatment with low dose radiation and chemotherapy, including Velcade, she has been steady since 2014.

Lisa, at the age of 49, is now reliant on a scooter to get around and is on oxygen 24/7. Despite her battles, she has a beautiful attitude towards life, facing her troubles with grace and bravery. In Lisa’s words: “Life is always an adventure, right?”

 

Len

Len suffered from symptoms for two years before receiving a diagnosis in 2012. After not feeling well, he visited a naturopath who helped alleviate some of his symptoms. He was having issues with his heart, and blood work showed a problem with his kidneys.

He was sent to a kidney specialist who ordered a biopsy. Within 24 hours he was given a diagnosis of Amyloidosis, with further testing showing it was AL. A bone marrow biopsy was also performed to rule out the possibility of multiple myeloma.

Thankfully, Len was admitted into a trial and received chemotherapy with melphalan, dexamethasone, and antibiotics. Within six months, he was in full remission!

Len has a great sense of humor and continues to spend time enjoying the things he loves. In Len’s words, “We power on as life can be short.”

 

Jan

Jan was diagnosed with AL Amyloidosis affecting her heart, skin, autonomic and peripheral nervous systems in 2009 at the Mayo Clinic in Rochester, MN. She visited Mayo after suffering from symptoms for over six years and was diagnosed within days.

Early symptoms included swelling, trouble walking, difficulty swallowing, tingling and numbness. According to Jan, some days, “it felt like her legs didn’t respond to her intentions for them to move.”

As her symptoms progressed, Jan had problems chewing and struggled to even open her mouth wide enough to eat. She was out of breath and lightheaded when standing, sometimes accompanied by lower chest pain. Jan suffered from severe fatigue and some days was unable to move her legs or lift her arms. Everyday activities required extreme concentration. Other symptoms included thinning hair, brittle fingernails, and stiff, painful hands.

She suffered from these symptoms for six years.  She faced x-rays, ultrasounds, MRI’s, CT scans, a stress test, an angiogram, an echocardiogram, and a pulmonary function test. As her health continued to decline, Jan’s doctor assured her things were normal and that she had the heart of a twenty-year-old.  Despite her doctor discouraging her, she decided to head to the Mayo Clinic.

Thank goodness she pushed through and advocated for herself! After four days of testing at Mayo, she was diagnosed with Amyloidosis.  In 2009, she had a partial response to her stem cell transplant. Two years later, after doctors discovered a blockage, she received a pacemaker.

In 2016, her light chains rose high enough that she needed another stem cell transplant. This time it was exceptionally difficult on her body. But after many issues and a lengthy hospitalization, Jan had a complete response. She is still in hematological remission today!

Although she still suffers from symptoms due to damage done to her heart, she is doing her best to lead a full life and is now “feeling back to her new normal.”

 

Janet  (not her real name – the patient asked to remain anonymous)

Janet received a diagnosis of Amyloidosis in June 2019, primarily affecting her kidneys and neurological system.

Her early symptoms included a lack of appetite, problems with bowel movements and sudden weight loss of 30 pounds. As her symptoms progressed, Janet suffered from low blood pressure and dizzy bouts and eventually would pass out upon standing. She had a tingling sensation between her toes, which progressed to constant, excruciating pain on the bottom of her feet.

Throughout the two years she searched for answers Janet visited many specialists. She had a colonoscopy, cardiac catherization, NCV, EMG, adrenal gland imaging, total body x-ray, blood tests, cardiac stress tests, heart monitor, skin biopsy, bone marrow biopsy, and a kidney biopsy.

Janet was dismissed at emergency rooms, with doctors saying her symptoms were either related to orthostatic hypotension or nothing.

She was misdiagnosed with MGUS and was being monitored by a hematologist because she had the markers for Multiple Myeloma.

As her symptoms continued to worsen, she visited her primary care physician who ordered a 24-hour urine sample. Janet was immediately sent to the emergency room when the results showed high amounts of protein in her urine. A kidney biopsy was performed and showed a diagnosis of Amyloidosis.

After facing CyBorD treatment, Janet is now on maintenance. Her neurological pain and weakness has worsened, and she is now using a walker.

She is too weak to be eligible for a stem cell transplant, but in Janet’s words “I’m hoping when I go back in June that this may change. Fingers crossed!”

 

Laura

Laura was diagnosed with AL Amyloidosis in the spring of 2018, at the age of 45. Her initial symptom was a chronic cough, which began six months earlier.  Diagnosed with asthma, Laura was treated with inhalers, nebulizers and steroids. The medications did nothing to improve her symptoms. As these issues continued, new problems emerged. Edema in her legs and ankles and an elevated BNP prompted her doctor to refer her to a cardiologist.

He tested and pursued answers until a diagnosis of Amyloidosis was confirmed. Because the Amyloidosis affects her heart, she has had an EKG, echocardiograms, a cardiac MRI, and a heart biopsy.

Laura’s last treatment was in October 2019. She is now monitored to ensure her levels remain normal. In Laura’s words: “I feel good most days. I know God is in control, so I try not to get too worked up.”

 

Conclusion

Amyloidosis presents itself in different ways with varying symptoms for each patient. Because of these differences, doctors often struggle to find an answer. If you are sick and searching for a diagnosis, please don’t give up. Follow your instincts, switch doctors, get second opinions, and keep going until you find out what is happening.

During my search, I was told it was anxiety and that my symptoms were all in my head. They were NOT. I was made to feel like I was irritating my doctor with my repeat visits. I was embarrassed and made to feel like I was too weak to handle life, that I was seeking attention, and exaggerating my symptoms. None of this was true.

I was sick and I needed help. I remember sitting in the parking lot of the hospital, too embarrassed to go in because I didn’t want to be dismissed and made to feel like I was crazy. So, I sat. I sat in that parking lot and cried because I couldn’t find someone who would help me.

Soon after, I realized that this is MY LIFE and other people’s opinions of me didn’t matter. In my gut I knew I was sick.  I went back to doctors, and clinics and the ER again and again and again and I demanded answers. Until one day, a wonderful hematologist said to me, “It is obvious that you are very sick.”

And with that statement I felt relief. You’d think my first instinct would be fear, but I felt relieved. Because I finally found someone who believed me. And I feel in my heart that this beautiful lady saved my life. I will be forever grateful to her.

If this resonates with you, your answers are out there too. Keep searching.

 

We are thankful to our fellow Amyloidosis patients for sharing their stories with us. Knowing that you are not alone can be an extraordinary help when faced with a scary diagnosis. If you or a loved one has been recently diagnosed with Amyloidosis, reach out to find support in those who genuinely understand your battles. It can make all the difference.

 

 

Lori Grover is a guest blogger for Mackenzie’s Mission. She was diagnosed with AL Amyloidosis in 2016 and writes to share experiences and lessons learned during her journey.  More wonderful blogs by Lori can be found on her page Amyloid Assassin.  Lori is a freelance copywriter, and a mom of two wonderful boys. She loves writing, reading, and all things crafty. 

2019: A Year of Impact!

Let me begin by saying THANK YOU for supporting Mackenzie’s Mission last year! It’s been a year of impact!

You may have donated cash or an auction item, bought a sponsorship, participated in one of our raising awareness campaigns, or played in our Play FORE The Cure charity golf tournament. You may have been an Amyloidosis Speakers Bureau speaker, donated your time volunteering for the tournament, Liked/Shared our Facebook posts, watched our FACES of Amyloidosis video, participated in our VOICES of Amyloidosis video, or taken the time to read our blogs to learn about amyloidosis. Whether you did one of these or many, you helped us push forward our fight against this disease and we appreciate your support.

 

HOW DID WE DO IN 2019?

This was our second full year of operation, busy and loaded with lots of activities to advance our mission — to make a difference in the fight against Amyloidosis. We work to make a difference in two ways.

  • Raise awareness about Amyloidosis, which we believe can lead to earlier diagnosis and better outcomes.
  • Support medical research on Amyloidosis, seeking the cause of the disease and more effective treatments to improve and extend lives.

 

Raising Awareness

In February 2019 we launched the Amyloidosis Speakers Bureau (ASB), the cornerstone of our raising awareness effort going forward. Our first year was an exciting one, surpassing our goals which we have summarized in our ASB: 2019 Year-End Review. I hope you will take a few minutes to read the Review and learn about our stunning progress! The ASB is directed by an operating committee of volunteers, the majority of whom are amyloidosis patients. The operating committee oversees the ASB’s program, predominantly the development of the medical school relationships and patient speakers. As ASB’s sponsor, Mackenzie’s Mission provides the operating and legal infrastructure, funding (from fundraisers, donations, and grants), and overall execution of the initiative.

In addition, we were busy launching videos and new blog posts (including those from our guest blogger Lori Grover).

 

The feedback we have received has been heartwarming and energizing. While being an inspiration to others is wonderful, we are moved by the conversations we have had with others affected by this disease. We share a common bond with uncommon experiences. Knowing we are not alone in this fight gives us all strength. Also, ASB testimonials we have received from medical students reinforces our thesis that education through patient stories strengthens their education about this disease which, we firmly believe, will positively impact the timeliness of future diagnoses and improve patient outcomes.

 

Supporting Medical Research

As we have said over and over, nothing happens in research without money. And knowing the NIH currently funds only 11% of its applications, this leaves a heavy burden on private foundations and individuals to help close the shortfall gap. So, our work to raise money matters.

  • Held our second annual Play FORE The Cure golf tournament, our sole fundraising event of the year.

A meaningful percentage of our monies raised (excluding grants) was donated to three world-class research institutions, with the balance supporting the Amyloidosis Speakers Bureau.

  • Mayo Clinic’s Amyloidosis Research Fund and Dr. Morie Gertz
  • Boston University’s Amyloid Research Fund and Dr. Vaishali Sanchorawala
  • Tufts Medical Center’s Amyloid and Myeloma Research Fund and Dr. Ray Comenzo.

 

WHAT ARE OUR GOALS FOR 2020?

Fundraising

  • On August 3, 2020 we will sponsor our third annual Play FORE The Cure charity golf tournament at the prestigious Robert Trent Jones Golf Club in the Washington D.C. area. Mark your calendars and come join us!
  • Solicit donations online, from Facebook fundraisers, and through mailings. Giving Tuesday and year-end giving are the most active times of year.
  • Secure grants to support the Amyloidosis Speakers Bureau.

 

Raising Awareness

  • Focus our energies on the Amyloidosis Speakers Bureau, expanding our medical school outreach. This is where we believe we can make the biggest impact from our efforts. Engagement from the amyloidosis patient community, securing meaningful grants, and sizeable proceeds from donations/fundraisers will be key to complement the operational and legal infrastructure required.
  • Develop FACES of Amyloidosis 2020 to celebrate Amyloidosis Awareness Month in March.
  • Continue to publish educational blogs and amyloidosis news.
  • Pursue speaking opportunities, both large and small, spreading the word on the importance of early diagnosis.

 

Supporting Medical Research

  • Donate a meaningful percentage of our donations and fundraising proceeds to leading research institutions whom we know are working to advance the knowledge and find answers about this disease.

I am encouraged by the impact Mackenzie’s Mission is already making. More than ever before we are connecting with the amyloidosis community and working together to make an impact. There is much work to be done, but with so much help from the community and our supporters I know we can win this fight!

With warm regards for a wonderful 2020,

Mackenzie

 

 

AN UPDATE ON ME

A year ago, in December 2018, I moved back to the Washington D.C. area after finishing a nearly two-year term as a research associate at Harvard Medical School. I learned an incredible amount about scientific research, its value, and the translation of the work back into the clinic. While in Northern Virginia, I have applied to medical school for Fall 2020 and am working through the process. I am very invested in Mackenzie’s Mission and our exciting Amyloidosis Speakers Bureau. I have spoken to students at Mayo Clinic, Tufts University, and University of Illinois, Chicago, and found each to be extraordinarily rewarding. I shadow an orthopedic trauma surgeon at Inova Fairfax Hospital, where I’ve been shadowing on and off for over seven years. In my spare time, I continue coaching youth hockey, something I have come to truly love, and volunteer as a head coach for a U19 girls ice hockey travel team. I am on an immunotherapy regimen to keep my disease at bay and continue to feel great.

ASB: 2019 Year-End Review

It’s been an exciting 11 months!! We have closed out 2019, nearly one year from our launch last February 1st, and we wanted to send a recap of how it went and what we see looking ahead for 2020.

Our mission is to educate future doctors about amyloidosis, with the belief that heightened awareness will lead to earlier diagnosis and ultimately improve patient survivorship. We know that the level of medical school education about amyloidosis runs the gamut, from a small mention in textbooks to classroom discussions with medical professionals, although the bias is overwhelmingly towards the “minor mention.” As a result, we are confident our efforts will provide students with a valuable enriched exposure to this disease to augment the medical school curriculum. 

The cornerstone of our effort is our group of patient speakers, who passionately volunteer their time to give back and share their stories of life with amyloidosis. Augmenting their real-life journeys, all students invited in our outreach can view an educational video on the disease and have access to a curated library of presentations by amyloidosis experts on the disease and diagnosis as well as numerous patient survivor stories. We so appreciate each and every one of our speakers!

We launched our initiative on February 1, 2019 and spent the first two months getting our operational and digital platform in place (www.mm713.org/speakers-bureau/ ). In April, we began emailing medical schools, developing our educational library, enlisting the support of expert advisors, and recruiting amyloidosis patient speakers.

We needed to build a platform for the ASB to support an ongoing annual initiative. In addition, knowing we were forging new territory we set a relatively modest goal for our first partial year, Fall semester 2019, which was to secure 15 medical school presentations. We are proud to say we accomplished both!  As you’ll read below, we now have an operational infrastructure for growth year-on-year. In addition, for the Fall semester 2019 we made 22 presentations, with our materials reaching over 4,200 medical students. Our first year — a success!

So let’s recap the details of what we accomplished in eleven short months. 

    • Reached out to 258 medical schools and student interest groups across the U.S.
      • 50% responded to our inquiries.  Of these,
        • 46% responded with some level of interest,
        • 32% passed us on to a colleague for consideration but never heard from anyone,
        • 9% said their curriculum was full and not open to new additions, and
        • 13% indicated they were not interested.
    • Scheduled 32 presentations, 22 were made in the Fall 2019 and 10 more are on the calendar for Spring 2020.  Another 10 are queued up to be scheduled for Spring 2020. 
      • According to the schools for these 32 presentations, the ASB educational information is estimated to reach around 6,200 students!
    • Names of schools scheduled include:
      • Central Michigan University College of Medicine
      • Cleveland Clinic Lerner College of Medicine
      • Columbia University Vagelos College of Physicians and Surgeons
      • Florida State University College of Medicine
      • Loyola University Chicago Stritch School of Medicine
      • Mayo Clinic Alix School of Medicine, Rochester
      • Mayo Clinic Alix School of Medicine, Scottsdale
      • NYU Grossman School of Medicine
      • Quinnipiac University Frank H Netter MD School of Medicine
      • Stanford University School of Medicine
      • Tufts University School of Medicine
      • University of Arizona College of Medicine, Phoenix
      • University of Colorado School of Medicine
      • University of Connecticut School of Medicine
      • University of Florida College of Medicine
      • University of Illinois College of Medicine, Chicago
      • University of Illinois College of Medicine, Peoria
      • University of Illinois College of Medicine, Rockford
      • University of Iowa Carver School of Medicine
      • University of Kansas School of Medicine, Wichita
      • University of Minnesota Medical School
      • UNLV School of Medicine
      • Virginia Commonwealth University School of Medicine
      • Wayne State University School of Medicine
      • Wright State University Boonshoft School of Medicine

 

  • Organized a semi-annual email to the Deans of all medical schools, queued for May and October. First one went October 2019.

 

  • Recruited 44 patient speaker volunteers across the U.S. with a wide array of types of amyloidosis, the most prevalent being AL and ATTR (both hereditary and wild-type). They have brought wonderful energy and transparency in sharing their stories, offering raw insights into managing through such a difficult disease. It’s a passionate commitment from them, paying it forward to those that follow. They are the priceless cornerstone of our success and we are endlessly grateful. A few of our speakers have summed it up so eloquently.

It was a pleasure to speak with 2nd year medical students about my experience as not only a cardiac AL survivor, but as a heart transplant survivor as well. I think the ASB is going to change the face of Amyloidosis and be instrumental in making strides in early diagnosis and treatment. 

I can think of little that is more rewarding in my medical journey than discussing this disease with those who might be in the position to recognize it in their patients now and in the future.

I was really looking for something good to come out of a personally bad situation. To be able to help raise awareness of future doctor’s is a great way of doing that.

 

  • Developed an educational library comprised of multiple components, with the emphasis of the content towards diagnosis rather than treatment. Documents include:
    • Amyloidosis Awareness – an introduction to amyloidosis, laying a broad foundation of the disease, developed by experts.  Note: the video of this, narrated by Michael York, is shown at the onset of every presentation.
    • A presentation on diagnosing amyloidosis (J. Mark Sloan, MD)
    • A presentation on diagnosis of amyloidosis (Maria Picken MD, PhD)
    • A presentation on amyloidosis and the kidney (Laura M. Dember, MD)
    • A presentation on cardiac amyloidosis (Martha Grogan, MD)
    • A presentation on cardiac amyloidosis (Brett W. Sperry, MD)
    • A presentation on What Every Cardiologist Needs To Know (Martha Grogan, MD)
    • A presentation on the diagnosis of amyloid cardiomyopathy (Kumal Bhatt, MD)
    • A presentation on Amyloid Polyneuropathy (Janice Wiesman, MD)
    • A presentation on Amyloidosis & the Gut (John O. Clarke, MD)
    • A presentation on ATTRwt Amyloidosis (Mat Maurer, MD)
    • A presentation on an Overview of hATTR (Fredric Ruberg, MD)
    • A presentation on the Central Nervous System and Ocular Involvement in hATTR (Chafic Karam, MD)
    • A presentation on pathology and laboratory testing for amyloid (Alton Farris MD, David Jaye MD)
    • A selection of patient survivor stories, highlighting their journey with the disease.

 

  • Received the support of 33 advisors who include medical experts and influencers in the world of amyloidosis, some of whom are also patients. A number of our advisors are active in our efforts and contribute their specialized expertise in a variety of ways, such as educational development, medical school introductions, and patient speaker assessment/development. We are so appreciative of their  support, offering powerful affirmation and credibility to our efforts. 

We have learned a few things from our early efforts which have helped us to adapt and to strengthen our offering. For example, we initially focused exclusively on getting integrated into the curriculum. We found that to be far more difficult, as curriculums are already dense and offer rare opportunities for adding in a one-hour segment for a rare disease. Thankfully, early on we learned about student interest groups (SIGs) as an alternative to reach a portion of the students. Thus our outreach is dual-focused: to those determining the curriculum and to the leaders of the relevant SIGs. In a second example, we initially thought that requiring students to read one presentation in advance was not too much of an ask. Wrong. We found that only 5-10% of students did so. Thus we shifted to have advance reading be optional, and we play a 10-minute Amyloidosis Awareness video at the onset of the presentation. The feedback from this adjustment has been well received. Gathering and listening to feedback, and being willing to pivot and adapt along the way, will continue to be an important part of our mindset.

Feedback from students and medical school organizers has been extraordinarily positive. It reinforces to us that the patient stories are a valuable complement to the medical school curriculum, strengthening the learning and deepening the durability for these future doctors about this disease. This is exactly why we do what we do. Here’s a glimpse into what students are telling us.

The presentation helped put a human face to a disease that is often only seen in test questions. You can easily forget a question, but it is much harder to forget a face.  Mayo Clinic Alix School of Medicine; Ramin Garmany, MD-PhD candidate

Amyloidosis is something we often call a “Zebra” disease. Its presentation is odd and confusing and its treatments few. Since AL is most treatable early, keeping it in your differential is so important. Having ASB talk at my school reinforced that idea. I believe that I will be a better physician for having attend this lecture.  University of Illinois College of Medicine Rockford; Rachel Miller, MD Candidate

It’s difficult to imagine as a student the impact of trying to find a diagnosis when your condition is so rare. Just hearing the first hand impact of trying to find a diagnosis was impactful. It was really valuable to hear two patient’s experiences, it reinforced the diversity of clinical presentations.  Tufts University School of Medicine; Kathryn Kompa, MD Candidate

Incredibly valuable to understand the patient’s journey throughout her disease progression. Her presentation made the hardships and resilience of an amyloidosis patient tangible and forced us to think about the disease as more than just facts presented on a powerpoint slide.  Loyola University Stritch School of Medicine, Alexandra E. Dereix, MD Candidate

This presentation was a wonderful supplement to my medical education because it brought amyloidosis to life and reminded me that there are actual people behind these devastating diseases. During the second year of medical school, it can seem very disconnected and abstract to study disease after disease and memorize the clinical presentations, treatments, and prognoses. It is refreshing to hear from an actual patient and be reminded of why we’re in medical school.  Loyola University Stritch School of Medicine, Alexis Stefaniak, MD Candidate

This experience gave me both a greater understanding of amyloidosis as a medical condition, as well as insight into how such a disease can affect someone’s quality of life. I think that after this presentation, I will be a more informed physician and a better advocate for my patients in the future.  Loyola University Stritch School of Medicine, Erin McCune, MD Candidate

This was an incredible experience full of insight; learning about amyloidosis from the patient perspective will aid me in becoming a more knowledgeable and empathetic physician in the future.   Loyola University Stritch School of Medicine, Katherine Bauer, MD Candidate

There is no learning tool more powerful than hearing a patient’s story for a disease. It not only puts a face to the condition, but the emotional memories you form from these experiences stick with you throughout your clinical years and beyond. Amyloidosis came to life during this presentation, and now we have the tools and knowledge to recognize it in our future patients. Having such a talented speaker and vetted resources allowed us to feel engaged and prepared to understand a condition that is not as rare or difficult to treat as we think!   Virginia Commonwealth University School of Medicine, Amber Domato, MD Candidate

 

Looking forward, we have quadrupled our goals for 2020 — to secure 60 presentations. We will start with the schools we have already presented to and discuss returning, and those schools that have voiced interest. Of course, we will continue our outreach to those we don’t have a dialogue with in hopes of a breakthrough.

We are proud of what we have accomplished in our first calendar year, thankful for the support from so many, and are energized about our potential. It truly is rewarding and exciting to be a part of helping to change the trajectory of this disease for future patients.

With warm regards,

Mackenzie, Charolotte, and Deb

 

The History of Congo Red

“Congo red is the essential histologic stain for demonstrating the presence of amyloidosis in fixed tissues. To the best of my knowledge, nothing has been written about why the stain is named ‘Congo.’ ” according to Dr. David P. Steensma.

So how did this stain get its name? Where did it come from, and does it have a connection to the African Congo? The history is fascinating and below, with Dr. Steensma’s permission, we adapt his story of the history of Congo red.

Congo red didn’t start its life as a histological stain nor was it initially named “Congo.” Like Prussian Blue, it was developed to dye clothes. In 1857, William H. Perkin in the UK created the first synthetic aniline dye, a purple color he called mauvine, later known as “mauve.”

 

Until that time, mostly natural dyes had been used to dye fabrics. After Perkin’s discovery, there was a race to create synthetic colors – mostly in Germany, mostly aniline dyes. This is the chemical structure of Congo red; aniline is a phenyl group attached to an amino group.

 

A major problem with older fabric dyes is that they wash out easily. To stop fading, another chemical, a mordant, is needed. Companies in the late 19th century were keen to find dyes that didn’t require a mordant, to save time and money. (A company in Connecticut sells this one.)

 

In 1883, a young German chemist, Paul Böttinger created a new bright-red dye that stained fibres without needing a mordant. He brought it to the attention of his bosses at The Friedrich Bayer Company but they weren’t interested. Reportedly they were looking for a purple, not red.

 

So Böttinger left Bayer and patented the chemical on his own. He offered it to several other companies, but they weren’t interested. Finally, a small Berlin-based dye manufacturing company called Agfa (Aktiengesellschaft für Anilinfabrikation), founded in 1867, bought it.

 

Congo red was a huge commercial success for Agfa – so much so that many other aniline dye companies went out of business. Bayer, the company that rejected Böttinger, only survived by creating their own Congo red … Agfa then sued them. (Clever sticker is from a Medium blog post.)

 

It became a classic case in patent law.  The “non-obvious” clause in patent world comes from Congo red.  Agfa and Bayer decided the lawsuit was becoming too expensive so they settled, agreed to co-market Congo red & share the profits. (This image is from http://chm.bris.ac.uk/motm/congo-red/congo-redh.htm…)

 

The lawsuits & lost sales had almost bankrupted Bayer. But now, with money from Congo red sales, Bayer was able to hire new chemists. In 1898 Bayer marketed heroin (!), and in 1899 they marketed a new drug you’ve probably heard of: aspirin. Heroin and aspirin saved the company.

 

In 1925 Bayer and Agfa and four other chemical companies merged to form IG Farben (Farben = colors/dyes in German). IG Farben made helpful chemicals like dyes and medicines, but also some terrible chemicals, like the infamous Zyklon B. As a result, they were dissolved after World War II.

 

The month Congo red was patented in 1885, there was a big event going on in Berlin: the Berlin West Africa Conference. In simple terms, the European powers were dividing colonial Africa. Otto von Bismarck, chancellor of the newly unified Germany, presided over the conference.

 

Britain & France already had established colonies; Italy controlled parts of East Africa, Portugal controlled Mozambique & Angola.  The Congo basin was a sticking point everyone was talking about. Some “genius” marketer at Bayer thought: what better name to give our new vivid dye?

 

Other dyes created at about the same time were Sudan Black, Sudan Red, Coomassie Blue, and Bismarck Brown – notice a theme? Africa = exotic and colorful in the late 19th century European mind. Incidentally, Sudan Black is also still used for histology, and Coomassie Blue in SDS-PAGE.

 

The real-world Congo was in the end given to the Belgian king, Leopold, as his private fiefdom. It became the site of some of the worst atrocities in human history, immortalized in Joseph Conrad’s book “Heart of Darkness”.

 

Anyway, Congo red, like many other aniline dyes, immediately started being used for histology. But it wasn’t particularly useful until 1922 when a young German pathologist, Hans Herman Bennhold, discovered it binds to amyloid. In 1929, Paul Divry, a Belgian neuropathologist studying degenerative changes in aging brains, first noted the characteristic green birefringence of amyloid substance when stained with Congo red and viewed under polarized light.  (This image is from Lai et al 2007 Kidney Int’l.)

 

 

General Principle of the Stain

According to Bitesize Bio,

Amyloid is similar in structure to cellulose, therefore it behaves similarly in its chemical reactions. It is a linear molecule, which allows azo and amine groups of the dye to form hydrogen bonds with similar hydroxyl radicals of the amyloid.

When examined in haematoxylin and eosin-stained sections of tissue, amyloid appears as an amorphous, glassy, eosinophilic material. Since this can be confused with some other materials, Congo red staining is needed to identify it.

When examined using regular bright-field microscopy, Congo red-stained amyloid appears pale orange-red. However, the bright field appearance alone is not diagnostic for amyloid, because small deposits may be difficult to see. Congo red-stained tissue sections must therefore be examined under polarised light allowing the characteristic ‘apple green’ birefringence to be seen which is diagnostic for the presence of amyloid.

 

Conclusion

Dr. Steensma writes “Congo red began its life as an extremely valuable textile dye – a dye of such importance that it not only revolutionized the textile industry but also resulted in a patent challenge that changed intellectual property law.” Decades later, the Congo red histologic stain is the gold standard today for the demonstration of amyloid in tissue sections.

Imagine that.

 

 

———————————-

Many thanks to Dr. Steensma for his permission to share this interesting story.

Reference:

“Congo” Red by David P. Steensma, MD; Archives of Pathology & Laboratory Medicine, 2001

 

 

 

 

Amyloidosis and Diet

While there is no special diet that will cure or treat Amyloidosis, both healthy eating and following doctor-recommended restrictions are essential. Guest blogger Lori Grover offers some tips on dealing with dietary changes.

 

According to Myeloma UK, eating a healthy diet increases energy levels, maintains muscle strength,  boosts your immune system and helps recovery after treatment. As you can see, making healthy choices makes sense. But easier said than done, right? Eating a healthy, balanced diet can be tricky for anyone. When your stress levels are high, and you feel horrible, making those necessary changes can be daunting. Because the disease affects everyone differently, your unique situation will determine the dietary suggestions that are made for you.

AL Amyloidosis can impact diet in a few ways.

  • Specific recommendations may be made as part of a plan to manage heart and kidney disease to prevent any further damage to organs
  • If kidneys are affected additional suggestions may be made to keep electrolytes in balance (especially if Dialysis is involved)
  • A low sodium diet and fluid restrictions may be suggested to combat edema
  • Certain foods or dietary supplements may be restricted because they interfere with medications
  • Dietary changes may be recommended to help deal with nausea, constipation, or diarrhea
  • A ‘clean diet’ may be advised if your white cell count is low (Avoidance of high-risk foods such as raw eggs, or shellfish)

 

Facing these dietary changes isn’t easy. Here are a few tips to ease the transition.

  • Look at it as a challenge.  Use it as an opportunity to try new foods, test out different cooking methods, and experiment with healthy recipes. Keep an open mind and try new things.
  • Focus on the foods you CAN eat rather than on the foods you can’t. Doctors and dieticians tend to give you lists of the foods you can no longer enjoy. While necessary, focusing on the things you can’t have can be depressing and overwhelming. Try to shift your focus and make a list of all safe foods and meals you can continue to enjoy. Having a go-to list on hand is useful when you’re feeling overwhelmed.
  • Create a collection of your favorite healthy recipes and try some new ones. Helpful websites to check out are Davita, Heart Foundation, and The Heart and Stroke Foundation. Experiment with new recipes and keep an open mind. If one fails, try, try again.
  • Meal plan, prep, and batch cook. Having ideas on hand makes mealtime easier. Some days you’ll have more energy than others. On those days, make extra and freeze and prep for other meals, so things will be all set for you when you’re feeling low.
  • Eat frequent, small meals throughout the day. Not only can it help if you’re feeling nauseous, but it also keeps you full and helps to avoid cravings. If you wait until you’re starving to eat, you’ll be more inclined to make bad decisions.

 

A low sodium diet may be recommended for both kidney and heart health.

Excess sodium in your diet contributes to fluid retention. Symptoms are swelling, puffiness, a rise in blood pressure, and shortness of breath (due to fluid around the lungs and/or heart).

The National Kidney Foundation recommends a maximum of 2300 mg of sodium per day and your doctor may recommend even less.

A balance must be struck to achieve an optimal sodium level for you, so follow your doctor’s recommendations carefully.  Limiting salt can be challenging, especially in the beginning, as your taste buds adjust. Keep at it and don’t give up…it will become your new normal.

 

Tips on dealing with a low sodium diet.

  • Avoid processed foods as much as possible. Read labels and choose lower-sodium varieties.
  • Eat whole foods and cook from scratch. Although it is more time consuming, cooking from scratch allows you to control the amount of salt.
  • Experiment with different spices and herbs to add flavour to your foods.
  • Add an acid when cooking, like a squeeze of lemon juice or vinegar to brighten flavours.
  • Pay attention to sauces, gravies, and salad dressings as they can contain a surprising amount of sodium
  • If potassium levels are a concern for you, be cautious with salt substitutes

 

A fluid-restricted diet may be advised to combat edema.

A common and severe side effect of AL Amyloidosis is fluid overload. This happens when you’re taking in more fluid than your kidneys can remove. A balance of restricting sodium and fluid, paired with diuretic medications, can help keep your fluid levels in check. In most cases, between 1.5-2 litres/ day of fluid is recommended.

Tips on dealing with fluid restriction

  • Fill a water bottle in the morning, and drink from it throughout the day to help you keep track of your water intake.
  • Keep a log (at least at the beginning) until you get an idea of how much fluid you are taking in, and don’t forget to include things like jello, watery fruit, and ice cream.
  • Plan to spread the fluid you drink throughout the day.
  • If dry mouth is a problem, ice chips, hard candies, and mouth rinses or sprays can help.

 

A low protein diet may be suggested to protect kidney health.

The goal is to strike a balance. While protein is necessary for growth and repair of your body, foods high in protein can add to the workload of the kidneys. When protein is digested, a waste product called urea is produced. If your kidneys are not functioning correctly, urea can build up in your bloodstream and cause further complications. For this reason, your doctor may suggest you limit your high protein foods.

Tips on dealing with a low protein diet:

  • Adjust the ratio of protein to vegetables in your recipes. Add more vegetables and starches to dishes such as soups and stews, to stretch it out and make it seem more substantial.
  • Think of vegetables and grains as the main dish, and protein as your side dish
  • Experiment with different types of protein, including plant-based options
  • Start a ‘meatless Monday’ as part of your routine, to test out vegetarian options

 

Specific foods and supplements may be limited.

  • You may have to cut out certain foods or supplements if they interact with the medications you are taking. For example, green tea and high dose Vitamin C can interfere with Bortezomib (Velcade) and make it less effective. Your doctor will give you a list of foods and supplements to avoid. Follow the recommendations carefully, and be sure to check with your medical team before adding any over the counter medications or supplements to your diet.
  • If your kidneys are affected, your levels of electrolytes and minerals will be closely monitored. Your kidney care team will make recommendations based on your levels. For example, you may have to avoid high potassium foods or those with high calcium levels.

 

There is no one size fits all diet for AL Amyloidosis. What is best for you will be decided based on your unique situation. Experts do agree that healthy eating has many benefits. And when you’re already facing so much, you want to do whatever you can to be your healthiest self.

The best take away tip I can give you is to keep an open mind and be ready to experiment. As you try new things and choose healthier options, you will adjust, and healthy eating will be your new normal.

For more tips on implementing these healthy changes check out our posts Tips & Recipes for Healthy Eating with Amyloidosis or our Treatment Survival Guide.

 

Resources

Myeloma UK handout                                                        The Heart Foundation

National Kidney Foundation

Heart and Stroke Foundation

Amyloidosis Foundation

Ted Rogers Heart Function

 

Lori Grover is a guest blogger for Mackenzie’s Mission. She was diagnosed with AL Amyloidosis in 2016 and writes to share experiences and lessons learned during her journey.  More wonderful blogs by Lori can be found on her page Amyloid Assassin.  Lori is a freelance copywriter, and a mom of two wonderful boys. She loves writing, reading, and all things crafty.

Play FORE The Cure 2019

Play FORE The Cure was designed to provide the ultimate player experience, from tip to toe. It was held at the world-class Robert Trent Jones Golf Club (RTJ), just outside of Washington D.C. in Gainesville, VA. RTJ’s PGA instructor Dennis O’Donovan held a golf clinic for the players. Players had a rich gift package, including $200 of Adidas merchandise, Tervis Tumblers, a Mackenzie’s Mission golf towel and RTJ/Mackenzie’s Mission coin ball marker. Fantastic contests with prizes including 5-day cruises and $10,000 cash gave the players plenty of motivation. A silent auction, thoughtfully curated with items including foursomes at courses such as RTJ, Kinloch Golf Club, and RiverBend County Club; golf equipment from Taylor Made; a beautiful handmade mahogany Gentlemen’s watch box; special half-case cabernet sauvignon bottles from Euclid Wines; fine jewelry from Washington Diamond; VIP package from Mecum Auctions; a weekend with a Bentley Bentayga; and a night in the Presidential suite at Ritz-Carlton added to the success. The evening program, emceed by my father Mark, included my keynote speech, where I shared the background behind Play FORE The Cure and why it’s so important.

The objective of the fundraiser was two-fold:

  • Support the newly launched Amyloidosis Speakers Bureau, focused on educating future doctors during their first/second year of medical school; and
  • Support research at multiple leading amyloidosis research institutions.

Raising money is central to every fundraiser. We maximized the monies raised through player registrations, sponsorships, donations, silent auction, 50/50 raffle, and mulligans. We amplified the net proceeds through the judicious management of expenses and generous donations of items and services.

In the end, we raised over $163,000!!!!

In addition, our efforts to raise awareness about amyloidosis took shape through easy-to-read pamphlets in player and volunteer gift bags (thank you Muriel and the Amyloidosis Support Groups!), and sharing the story of my journey and the disease. Over 80 people have now been introduced to amyloidosis, a rare and incurable disease.

We are grateful for the contributions of our supporters, which include sponsors, auction donors, cash donors, and wonderful volunteers. We are also particularly appreciative of the support from local amyloidosis patients, offering their time and involvement to ensure success! Thanks to RTJ for hosting us at your beautiful world-class venue, and of course, a big thank you to our players who enjoyed the full day of activities!

We look forward to seeing you next year, and thank you everyone for your support.

With my warmest regards,

Mackenzie

 

10 Signs You Might Have Amyloidosis

What is amyloidosis and 10 signs you might have it

October 15, 2019, from the Mayo Clinic News Network

Amyloidosis (am-uh-loi-DO-sis) is a rare disease that occurs when a substance called amyloid builds up in your organs. Amyloid is an abnormal protein that is produced in your bone marrow and can be deposited in any tissue or organ.

Amyloidosis frequently affects the heart, kidneys, liver, spleen, nervous system and digestive tract. It is often overlooked because it may cause no symptoms at first. And when there are signs or symptoms, they can look like those of more-common diseases.

There’s no cure for amyloidosis and severe amyloidosis can lead to life-threatening organ failure. But treatments can help you manage your symptoms and limit the production of amyloid protein.

Diagnosis as early as possible can help prevent further organ damage caused by the protein buildup. So, it’s important to talk with your health care provider if you’re experiencing any of these 10 possible signs and symptoms.

  • Urine changes and swollen legs. If amyloidosis damages your kidneys, it can cause protein to leak from your blood into your urine. This may cause your urine to be foamy, or you may urinate less.When large amounts of protein leave your bloodstream and enter your urine, water can leak out of the blood vessels into your feet. This can cause your feet, ankles and calves to swell.
  • Unintentional, significant weight loss. If you’re losing protein from your blood, you may lose your appetite and, as a result, lose weight without trying.If amyloidosis affects your digestive system, it can also affect your ability to digest your food and absorb nutrients. It’s common to lose 20 to 25 pounds.
  • Severe fatigue. Feeling extremely tired is common with amyloidosis. Even small efforts may feel difficult.
  • Shortness of breath. If amyloidosis affects your heart, it can limit your heart’s ability to fill with blood between heartbeats. This means less blood is pumped with each beat, which may cause you to feel short of breath. Amyloidosis that affects the lungs also can cause shortness of breath.You may find it difficult to climb a flight of stairs or walk long distances without stopping to rest. You may also feel short of breath with even the slightest activity.
  • Numbness, tingling, weakness or pain in your hands or feet. If amyloid proteins collect in and put pressure on the nerves to your fingers, you may have pain and other symptoms in your wrists (carpal tunnel syndrome). If the amyloid proteins collect in the nerves to your feet, you may have numbness, lack of feeling, or a burning sensation in your toes and soles of your feet.
  • Diarrhea or constipation. If amyloidosis affects the nerves that control your bowels, you may have diarrhea or constipation.
  • An enlarged tongue. Amyloidosis can cause your tongue to become enlarged. It can also cause other muscles, such as in your shoulders, to become enlarged.
  • Skin changes. You may notice a waxy thickening of your skin; easy bruising of your face, eyelids or chest; or purplish patches around your eyes.
  • Irregular heartbeat. If amyloidosis affects your heart’s electrical system, it may disturb your heart’s rhythm and cause an irregular heartbeat.
  • Dizziness when standing. If the nerves that control your blood pressure are affected, you may feel dizzy or near fainting if you stand up too quickly.

Many of these signs and symptoms may be caused by other conditions. But if you experience any of them, talk with your health care provider about whether they might be caused by amyloidosis. And if you have a family history of the condition, be sure to tell your health care provider. Come to your appointment ready to discuss your symptoms and when they happen.

Causes

In general, amyloidosis is caused by the buildup of an abnormal protein called amyloid. Amyloid is produced in your bone marrow and can be deposited in any tissue or organ. The specific cause of your condition depends on the type of amyloidosis you have.

There are several types of amyloidosis, including:

  • AL amyloidosis (immunoglobulin light chain amyloidosis) is the most common type and can affect your heart, kidneys, skin, nerves and liver. Previously known as primary amyloidosis, AL amyloidosis occurs when your bone marrow produces abnormal antibodies that can’t be broken down. The antibodies are deposited in your tissues as amyloid, interfering with normal function.
  • AA amyloidosis mostly affects your kidneys but occasionally your digestive tract, liver or heart. It was previously known as secondary amyloidosis. It occurs along with chronic infectious or inflammatory diseases, such as rheumatoid arthritis or inflammatory bowel disease.
  • Hereditary amyloidosis (familial amyloidosis) is an inherited disorder that often affects the liver, nerves, heart and kidneys. Many different types of gene abnormalities present at birth are associated with an increased risk of amyloid disease. The type and location of an amyloid gene abnormality can affect the risk of certain complications, the age at which symptoms first appear, and the way the disease progresses over time.
  • Dialysis-related amyloidosis develops when proteins in blood are deposited in joints and tendons — causing pain, stiffness and fluid in the joints, as well as carpal tunnel syndrome. This type generally affects people on long-term dialysis.

Risk factors

Anyone can develop amyloidosis. Factors that increase your risk include:

  • Age. Most people diagnosed with AL amyloidosis, the most common type, are between ages 60 and 70, although earlier onset occurs.
  • Sex. Nearly 70 percent of people with AL amyloidosis are men.
  • Other diseases. Having a chronic infectious or inflammatory disease increases your risk of AA amyloidosis.
  • Family history. Some types of amyloidosis are hereditary.
  • Kidney dialysis. Dialysis can’t always remove large proteins from the blood. If you’re on dialysis, abnormal proteins can build up in your blood and eventually be deposited in tissue. This condition is less common with modern dialysis techniques.
  • Race. People of African descent appear to be at higher risk of carrying a genetic mutation associated with the type of amyloidosis that can harm the heart.

This article is written by Mayo Clinic staff. Find more health and medical information on mayoclinic.org.

Here’s the original article posted in the Mayo Clinic News Network

Support Groups: Can They Play A Role In Your Treatment?

Have you recently been diagnosed with Amyloidosis? Wondering if joining a support group, whether online or in person, would be right for you?

When I was diagnosed with AL Amyloidosis, I thought that it wouldn’t be for me. It took me over a year to join. I had a picture in my mind of what it would be like. I envisioned a group of people gathered together to complain about how sick they were. I was afraid to get a glimpse of my future. I pictured a giant pity party.

What I experienced was extremely different. These groups are full of survivors! They are handling this disease with the most positive attitude possible and are making the best of the hand they have been dealt. I have learned so much from these people.

In these groups, you will find people who have been where you are, recently diagnosed, scared, and overwhelmed. You will find people willing to share the tips and tricks that helped them face some of their darkest moments and most difficult times. You will find people to help support and encourage you through your journey.

To find out more about the role of the support group, I reached out to Muriel Finkel from the Amyloidosis Support Groups (ASG) and Marsha McWhinnie from the Canadian Amyloidosis Support Network (CASN).

 

WHO IS THE SUPPORT GROUP FOR?

Support groups are for patients with all types of Amyloidosis and their caregivers. Their websites are full of information and resources. Online support groups such as the Amyloidosis Support Groups on Facebook, CASN, Smart Patients, and One Amyloidosis Voice are private and require access permission by the administrators. Such security for access offers comfort for the participants to reveal more personal information. In person support groups provided by Amyloidosis Support Groups, CASN, and the Amyloidosis Foundation, offer additional services and support for patients, as well as access to expert medical professionals.

 

WHAT IS THE GOAL OF THE SUPPORT GROUP?

Support groups, in general, are concerned with awareness and education. Their goal is to educate and empower patients, promote awareness, support medical research, and to improve the quality of life for those with Amyloidosis.

 

WHAT SERVICES DO SUPPORT GROUPS PROVIDE?

  • Both ASG and CASN operate a toll – free number, the primary goal of which is to provide a compassionate, understanding ear to those recently diagnosed. If you have received this life-altering and scary diagnosis, this call can let you know you are not alone and that there is hope.
  • Their websites provide educational videos and articles, medical referrals, patient stories, links to Amyloidosis support resources, and lists of upcoming meetings.
  • Both groups host support group meetings, which provide an opportunity to meet other patients and caregivers. During these meetings, an Amyloidosis expert presents, and there is an opportunity to ask questions and share your story. The ASG hosts meetings throughout the United States and the CASN has meetings in Toronto and Quebec.
  • The Amyloidosis Support Group also holds a special meeting for ATTR in Chicago every two years, with the top experts in the country participating and presenting.
  • ASG sponsors multiple groups on Facebook so patients and caregivers can chat with each other, share stories, and ask questions. These groups are mediated by wonderful volunteers who are up to date with the latest treatments and advances in the field, with assistance from medical advisors. The groups on social media allow patients from all over the world to connect.
  • Smart Patients is an online forum with conversations among the amyloidosis community, with topics ranging the full gamut from symptoms to treatment.
  • A new online community was recently launched called ‘One Amyloidosis Voice,’ which has a message board, social wall, trusted resources, a news and meetings section, and a diagnosis educator.
  • Through online forums and participation in local events, Support Group administrators and volunteers spread the word about Amyloidosis, with the goal of increased awareness.
  • Both groups are interested in supporting medical research by sharing information about clinical trials with patients. Pharmaceutical reps are sometimes present at meetings to answer questions, and to help connect patients with trials that might be right for them.

 

WHAT A TYPICAL SUPPORT GROUP MEETING LOOKS LIKE

Although each meeting varies and ends up with a flow of its own, administrators do follow a basic outline which includes the following:

  • New Business – A discussion of what is new in the field of Amyloidosis and what the Support Group has been working on
  • Guest Speaker – An interactive presentation from an Amyloidosis expert (usually a doctor or other medical professional)
  • Question and Answer Period – Questions are encouraged, and one on one time with the presenter may be possible
  • Meal or snack is provided (depending on the timing of the meeting)

The atmosphere is laid back and comfortable, and patient confidentiality is paramount. It is absolutely your choice as to whether you share your story and ask questions.

 

BENEFITS OF THE SUPPORT GROUP

  • You hear inspiring stories which can provide comfort and hope for the future.
  • You are kept up to date with the treatments, clinical trials, and medical breakthroughs.
  • You can share your story with people who genuinely get it.
  • You can ask for help if you have questions. Facing symptoms and looking for relief? Concerned about a new symptom or side effect? Chances are there is someone in the support group who has faced it and can offer help and support.
  • You can find information on what to expect from treatment. There are people in these groups who have endured stem cell transplants, chemotherapy, and have participated in clinical trials. In some cases, patients have tried various types of treatments and can offer suggestions of what to expect, and how to deal with side effects.
  • You can also find information on the leading Amyloidosis Specialists and Centres of Excellence. Because Amyloidosis is such a rare disease, it is vital to get the experts on your team.
  • Need to vent? We do that too. Sometimes it just becomes too much. The weight of it all hits and you feel overwhelmed and lost. There’s someone here who can provide a listening ear.

I am so glad that I decided to join these support groups. Not only do I get to hear the inspiring stories of those who are making life happen despite the challenges they face, but I have learned SO MUCH.  Amyloidosis patients who have been living with this disease for years have a wealth of information. The administrators of the groups are also up to date with current treatments, clinical trials, and medical breakthroughs happening in the field of Amyloidosis.

I have met people whose advice has helped me through challenging times. There is something special about talking with someone who has been where you are now. Someone who has received the same diagnosis and faced the same overwhelming feelings of fear and uncertainty. To know that others have been where you are and have come out the other side is comforting and inspiring.

Thanks to these support groups I know I am never alone.

 

 

How to contact a support group near you

Amyloidosis Support Group

http://www.amyloidosissupport.org/

1-866-404-7539

Canadian Amyloidosis Support Network

http://thecasn.org/

1-877-303-4999

Amyloidosis Foundation

http://amyloidosis.org/resources/#websites-and-support-groups

One Amyloidosis Voice

https://www.oneamyloidosisvoice.com/

Smart Patients

https://www.smartpatients.com/

 

Lori Grover is a guest blogger for Mackenzie’s Mission. She was diagnosed with AL Amyloidosis in 2016 and writes to share experiences and lessons learned during her journey.  More wonderful blogs by Lori can be found on her page Amyloid Assassin.  When not writing, she is mostly a stay at home mom, florist, crafter, lover of books and food. Enjoy!

 

Amyloidosis By The Numbers

 

As a member of the amyloidosis community, we consistently engage in conversations with patients across a variety of forums. One constant among these patients is a desire for more knowledge. We want to learn about symptoms, treatments, and how we are all impacted by this disease. To get some answers, Mackenzie’s Mission created a series of online questions. We heard from 575 respondents. Here are their answers.  Disclaimer: we are simply reporting the data as submitted.

 

In response to what is your current age today, the range was between 20 and 89, with 92.6% falling between the age of 40 and 79, and 83% falling between the age of 50 and 79.

 

 

In response to what was your age at time of diagnosis, the range was between 10 and 89, with 91% falling between the age of 40 and 79, and 63.8% falling between the age of 50 and 69.

 

 

The gender of respondents was somewhat balanced, with 54.5% female and 45.5% male.

 

 

The respondents currently live in 25 countries/areas around the globe, with 82.09% from the United States.

 

 

The types of amyloidosis were also diverse, including Primary/AL, hATTR, ATTRwt, Localized, and Secondary/AA.  About 3% of the respondents were types outside of these, or unknown.

 

When asked about the number of organs affected, the majority at 56.5% had two or more, followed by 36.7% with one organ involved. A small 6.8% had no organ involvement.

 

Next, we asked the respondents for specifics as to which organs had been affected by the disease. The heart and kidney were the most common, with the GI Tract and Nervous System coming in similarly at third and fourth. Fewer respondents listed problems with the liver, lungs, spleen and larynx. In addition, there was a surprisingly long list of other involvements filled in, each receiving just one tally.

 

The next four questions focused on the specialty of doctors that patients had visited, and the time to diagnosis.  We first asked how many doctors each respondent saw before getting a diagnosis. It is interesting to see how evenly it is spread across the selections.

 

We then wanted to know where their journey began. What was the specialty of the first doctor the respondent visited?  It was not a surprise that the majority of responses, at 53.9%, named their PCP/Internal Medicine as their first stop.

 

The next question was to determine what type of doctor made the amyloidosis diagnosis. The data seems to indicate that while PCP/Internal Medicine was the first point of inquiry at 53.9%, they arrived at a diagnosis only 1.9% of the time. Thus, referrals to specialists were key to getting a diagnosis, with nephrologists, hematologists/oncologists, and cardiologists the front runners at an aggregate of 72.9%. Having said that, per the earlier chart, it took many specialists to arrive at the answer.

 

Next, we wanted to know how long it took to get a diagnosis. We were surprised to learn that 50% of respondents said they received a diagnosis within the first six months, especially given the number of doctors visited to arrive at the diagnosis.

 

We then asked respondents to list all symptoms they experienced. The dominant symptoms were fatigue and shortness of breath – 64.2% and 53.7% respectively. The “Other” category came in strong at 22.4%, with an extremely long and diverse list of additional symptoms (too many to mention here). It does seem appropriate to observe that the diversity of symptoms reflects the complexity of this disease.

 

We wanted to better understand how long patients experienced symptoms before they sought medical attention (this is of course with the benefit of 20/20 hindsight). Some 37.6% of respondents sought treatment early, waiting six months or less. However, nearly half — approximately 46% — experienced symptoms anywhere from six months to three years before their first doctors visit.

 

We asked respondents the types of treatments they had undergone since diagnosis. A significant 77.8% had various types of drug therapy and 37% received a stem cell transplant. A number of the patients having a stem cell transplant also had drug therapies, so these responses are not exclusive of one another.

 

For those who underwent a stem cell transplant, we wanted to understand whether the procedure was done as an inpatient, an outpatient, or as a combination. The majority at 68.5%, for a variety of reasons, were inpatient.

 

Our next category of questions focused on clinical trials.  Of our 575 respondents, roughly one-quarter have participated in a clinical trial.

 

We asked those who participated in a clinical trial which one they were in. You can see below the distribution for the ATTR trials. We did ask a separate question regarding the AL-focused trials, however the data proved to be questionable and thus it was excluded from this recap.

 

The next question was aimed at the 77% who indicated they did not participate in a clinical trial, seeking to understand why not.  Striking was the number of respondents who declined, for whatever reason, to answer.

 

In the next question we asked respondents to provide some insight into how they rated their ability to tolerate treatment, whatever that may be. It was spread out, perhaps due to a wide range of treatments.

 

We then asked patients to assess their quality of life before and after treatment. For those that responded, the majority indicated at least a moderate improvement.

 

 

In our next-to-last question we asked the current state of their disease.

 

The final question was open-ended, where we asked respondents to complete the following sentence: “With hindsight, I would have appreciated knowing about …”  We received a massive number of responses, and in our desire to give everyone their full and unedited voice, we invite you to read through the many heartfelt and authentic voices (listed in the order received).   “With hindsight, I would have appreciated knowing about …”

 

 

CLOSING THOUGHTS

 

The responses we got from this study reinforce the complexity and diversity of amyloidosis. To each member of this community who stepped forward to answer the questions, we thank you. Gathering information, spreading awareness, and pushing for change leads us on the path to earlier diagnosis and an increase in life-saving research.

 

One repeating point people mentioned in the last question was a need for more information for doctors and members of the medical community, and for patients and caregivers who are dealing with this disease. If we continue to reach out to doctors, they will recognize the symptoms of amyloidosis and will think to test for it, leading to earlier diagnosis. If we continue to provide patients and caregivers with the most up to date information on treatments, resources, and where they can go for support, we can help arm those who are newly diagnosed. In this way, the sharing of information can be one of our most valuable tools.

 

Fight on, amyloidosis warriors. Fight on.

 

ASB: Our First Six Months

It’s been a quick six months since we launched the Amyloidosis Speakers Bureau, and we wanted to provide an update about our progress and all we have accomplished so far.

 

Our mission is to educate future doctors about the disease, through both a patient speaker and an educational packet. Each year we will reach out to medical schools across the U.S., first asking to present to their students within their curriculum, but if that is not possible, we are finding success through their student interest groups.

 

We started our initiative on February 1, 2019 and spent the first two months getting our operational and digital platform in place (www.mm713.org/speakers-bureau/ ). In April 2019, we began emailing medical schools, developing our educational packet, and recruiting amyloidosis patient speakers.

As of August 1, 2019, here are the numbers for our 2019-2020 school year.

  • Reached out to 194 medical schools and student interest groups.
    • 46% have responded to our inquiries.  Of these,
      • 33% responded with interest,
      • 42% have passed us on to a colleague for consideration and we are waiting,
      • 10% have said their curriculum is full this year and not open to new additions, and
      • 15% have indicated they are not interested.
    • 10 presentations have been scheduled, 4 are in the queue to be scheduled, and more are expected.
      • According to the schools, these 10 presentations have the potential to educate 1,350 students. As future presentations are added to the calendar, this number will obviously increase.

 

  • Recruited 34 patient speaker volunteers across the U.S., with a wide array of types of amyloidosis. 

 

  • Developed an educational packet comprised of seven components. The emphasis of the content is towards diagnosis rather than treatment.
    • An introduction to amyloidosis, laying a broad foundation of the disease, developed by experts in the industry
    • A presentation on diagnosing amyloidosis 
    • A presentation on amyloidosis and the kidney
    • A presentation on cardiac amyloidosis
    • A presentation on the diagnosis of amyloid cardiomyopathy
    • A presentation on pathology and laboratory testing for amyloid
    • A selection of patient survivor stories, highlighting their journey with the disease

 

  • Received the support of 30 advisors, who include medical experts, influencers, and patients in the world of amyloidosis. A number of our advisors are active in our efforts and contribute their specialized expertise in a variety of ways, such as educational development, medical school introductions, and patient speaker assessment/development. 

 

Much work remains to get a connection with the remaining 54% of our universe, and each week, we advance our outreach efforts. We anticipate our push for the current school year will continue throughout the fall, and then in the spring of 2020, we will be starting our push for the 2020-2021 school year, reaching out to all schools and student interest groups.

 

We are proud of what we have accomplished in our first six months, and are energized about our potential. We will be collecting feedback and data on our efforts, adapting our approach where appropriate, and expect increasing success over time.

 

We wanted to extend a special thank you to our speakers, for without them, there would be no ASB. They are an integral part of making the ASB a success by helping to change the trajectory of diagnosing this disease and increasing patient survivorship. We are proud to have them on the team. If you are a patient in the U.S. and interested in joining our initiative, please email us at asb.mm713@gmail.com. We’d love to talk!
 
Be sure to follow us and track our progress, whether it be by signing up for our Mackenzie’s Mission mailing list, or following us on Facebook.
With warm regards and much appreciation. 
Mackenzie, Charolotte, and Deb
This website uses cookies

This site uses cookies to provide more personalized content, social media features, and ads, and to analyze our traffic. We might share information about your use of our site with our social media, advertising, and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will never sell your information or share it with unaffiliated entities.

Newsletter Icon